Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Apr;30(3):137-147.
doi: 10.1089/cap.2019.0125. Epub 2019 Dec 16.

Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder

Affiliations
Randomized Controlled Trial

Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder

Tanya E Froehlich et al. J Child Adolesc Psychopharmacol. 2020 Apr.

Abstract

Objective: We sought to ascertain whether baseline anxiety/depression and oppositional defiant disorder (ODD) symptoms impacted the experience of short-term methylphenidate (MPH) adverse effects (AEs) in 7- to 11-year-old children with attention-deficit/hyperactivity disorder (ADHD) (n = 171) undergoing a double-blind MPH crossover trial. Method: The Vanderbilt ADHD Diagnostic Parent Rating Scale measured baseline child anxiety/depression and ODD symptomology. The parent-completed Pittsburgh Side Effect Rating Scale assessed the AEs of anxiety, sadness, and irritability at baseline, on placebo, and on three MPH dosages. For each AE, we evaluated comorbidity main effects, dose main effects, and comorbidity × dose interactions. Results: Baseline anxiety/depression × dose and ODD × dose interactions were significant for the AEs of anxiety, sadness, and irritability. Compared with premedication baseline, these AEs attenuated on MPH for children with initially higher comorbidity symptoms, whereas those with initially lower comorbidity symptoms tended toward no change or increasing AE levels. Conclusion: Premedication anxiety/depressive and ODD symptoms may be important predictors of short-term MPH emotional AEs.

Keywords: ADHD; adverse effects; methylphenidate; side effects; stimulants.

PubMed Disclaimer

Conflict of interest statement

Dr. Epstein has received research support from Akili Interactive Labs, received royalties from Multi-Health Systems, Inc., received consulting fees from the American Academy of Pediatrics and American Board of Pediatrics, and received licensing fees from Optimal Medicine, Inc. and IXICO. Dr. Froehlich, Dr. Brinkman, Dr. Peugh, Ms. Piedra, and Mr. Vitucci have no conflicts of interest or financial disclosures.

Figures

FIG. 1.
FIG. 1.
Anxiety adverse effect ratings during baseline, placebo, and high dose methylphenidate conditions by level of premedication anxiety/depression symptoms. ln, natural log of adverse effect rating, with dashed lines indicating the ln score that corresponds to adverse effect parent ratings of mild, moderate, and severe. SD, standard deviation.
FIG. 2.
FIG. 2.
Sadness adverse effect ratings during baseline, placebo, and high dose methylphenidate conditions by level of premedication anxiety/depression symptoms. ln, natural log of adverse effect rating, with dashed lines indicating the ln score that corresponds to adverse effect parent ratings of mild, moderate, and severe. SD, standard deviation.
FIG. 3.
FIG. 3.
Irritability adverse effect ratings during baseline, placebo, and high dose methylphenidate conditions by level of premedication ODD symptoms. ln, natural log of adverse effect rating, with dashed lines indicating the ln score that corresponds to adverse effect parent ratings of mild, moderate, and severe. ODD, oppositional defiant disorder; SD, standard deviation.

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994
    1. Barkley RA: Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (3rd ed). New York (NY), The Guilford Press, 2006
    1. Becker SP, Langberg JM, Vaughn AJ, Epstein JN: Clinical utility of the Vanderbilt ADHD diagnostic parent rating scale comorbidity screening scales. J Dev Behav Pediatr 33:221–228, 2012 - PMC - PubMed
    1. Brinkman WB, Simon JO, Epstein JN: Reasons why children and adolescents with attention-deficit/hyperactivity disorder stop and restart taking medicine. Acad Pediatr 18:273–280, 2018 - PMC - PubMed
    1. Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH: Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 25:611–617, 2015 - PMC - PubMed

Publication types

MeSH terms

Substances